EMA sounds its own safe­ty alarm for Pfiz­er block­buster, but they’re al­so not forc­ing a lim­it on dos­ing — yet

The Eu­ro­pean Med­i­cines Agency has is­sued a for­mal warn­ing for pa­tients and physi­cians to stick with the rec­om­mend­ed dose of Xel­janz for treat­ing rheuma­toid arthri­tis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.